2011: Ipilimumab: First Checkpoint Inhibitor Approved (2011)
The FDA approval of ipilimumab (Yervoy) for metastatic melanoma in March 2011 launched the
checkpoint inhibitor era, arguably the most consequential revolution in cancer therapeutics since
the introduction of cytotoxic chemotherapy. Ipilimumab is a fully human monoclonal antibody that
blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4), an inhibitory receptor expressed on T cells.
The conceptual foundation came from James Allison at the University of California, Berkeley, who
in 1995 demonstrated that antibody-mediated CTLA-4 blockade could augment antitumour immune
responses and cause regression of established tumours in mice—despite broad scepticism from the
oncology community, which had largely abandoned immunotherapy after decades of modest results.
CTLA-4 is upregulated on activated T cells and functions as an immune checkpoint: it competes with
the co-stimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells,
delivering an inhibitory signal that dampens T-cell activation and prevents autoimmunity. By blocking
CTLA-4, ipilimumab removes this brake, enabling more robust and sustained cytotoxic T-cell responses
against tumour antigens. The drug does not target the tumour directly but rather enhances the host
immune system's capacity to recognise and destroy cancer cells.
The pivotal Phase III trial in previously treated metastatic melanoma demonstrated an overall survival
benefit—a first for any systemic therapy in this indication. Crucially, the survival curves showed
a characteristic "plateau" beyond three years: approximately 20 % of patients treated with
ipilimumab achieved durable long-term survival, some surviving more than ten years, a pattern
unprecedented with chemotherapy. The drug also introduced a new category of immune-related adverse
events (irAEs)—colitis, hepatitis, endocrinopathies, pneumonitis—requiring specific management
protocols and reflecting the loss of peripheral immune tolerance.
James Allison shared the 2018 Nobel Prize in Physiology or Medicine with Tasuku Honjo, who
independently discovered the PD-1 pathway.
यह क्यों महत्वपूर्ण था
Ipilimumab proved that releasing immunological brakes could produce durable tumour regression and
long-term survival in a cancer previously resistant to all systemic therapy. It established immune
checkpoint blockade as a new treatment modality, created a template for the anti-PD-1 and anti-PD-L1
antibodies that followed, and—through Allison's Nobel Prize—validated basic immunological research
as a direct route to transformative clinical breakthroughs.